outcomes, activation of the complement system has been shown to play a central role in BD-associated graft injury. [9] [10] [11] In preclinical and clinical studies of both heart and kidney transplantation, grafts from BD donors were not only associated with more severe ischemia-reperfusion injury (IRI), but posttransplant pathology was also shown to significantly correlate to the level of complement activation. 4, [10] [11] [12] [13] Given these findings, inhibition of the complement cascade has been studied in the context of BD and transplantation, 10, [14] [15] [16] [17] and it has been shown that donor therapy or graft-targeted inhibition improves posttransplant outcomes. 10, 17 To date, very little is known regarding the role of BD-induced lung injury in LTx and nothing is known in the context of complement activation. A handful of studies have explored the potential for complement inhibition (C-Inb) in LTx exclusive of BD, [18] [19] [20] [21] [22] showing beneficial impacts on early outcomes and the development of obliterative bronchiolitis when complement inhibitory strategies are administered systemically. 22, 23 The lung, unlike other solid organ transplants, is open to the environment, which has two specific implications: (1) it lends itself to localized focused drug delivery via nebulization, and (2) it is constantly exposed to environmental irritants and potential pathogens. Given the latter, systemic or localized C-Inh in the early posttransplant period may well have unique challenges due to the potential for increased risk of infection.
To this end, we sought to study the role of complement in BD and
LTx IRI, specifically focusing on C3a, a split-product of the central complement protein C3. C3a, via its interaction with C3a receptor (C3aR), is a potent anaphylatoxin that can drive and enhance both innate and adaptive immune responses. 24, 25 We focused on C3a because inhibiting its functions would decrease inflammation while maintaining complement-dependent pulmonary pathogen defense mechanisms, such as complement opsonization. 26 Here we show that BD activates an inflammatory response and the complement system, which worsened post-LTx outcomes. Furthermore, therapeutic blockade of C3aR ameliorated BD-associated IRI posttransplantation when delivered directly to the BD donor lung prior to transplantation.
| ME THODS

| Animals
Eight-to 12-week-old BALB/c and C57BL/6 mice weighing 25-30 g were purchased from Charles River Laboratories. Animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences. Three study groups were utilized: (1) living donor control; (2) vehicle-nebulized BD donors; and (3) C3aR antagonist (C3aRA) (Cal Biochem, Darmstadt, Germany) nebulized brain-dead donors (1 mg/mL). Each donor was either nebulized with C3aRA reconstituted in PBS:DMSO solution at a dose of 1 μL/g body weight (n = 6 all groups), which was extrapolated from our previous studies, 26, 27 or PBS:DMSO vehicle.
| Rodent surgical procedure
BD was induced in donor mice with a Fogarty catheter balloon as previously described. 10 Donor animals with refractory hypotensive episodes, defined as mean arterial pressure <50 mmHg for a duration of longer than 20 mins, were excluded from the studies, as we have previously described. 11 Nebulization was performed on BD donor mice 30 minutes prior to harvest using an in-line nebulizer (emka Technologies, Falls Church, VA) attached to the inspiratory tubing of the ventilator (Physiosuite, Kent Scientific, Torrington, CT). Donor left lungs were procured as previously described 28, 29 and stored for 18 hours in Perfadex (XVIVO Perfusion Inc., Englewood, CO) at 4°C
prior. Donor left lungs were then prepared for transplantation and left orthotopic vascularized lung transplants performed utilizing cuff techniques into C57Bl/6 recipient mice, as previously described. 28, 30 Allografts were harvested at 6 hours or 5 days post-LTx for analysis.
To determine the degree of donor lung injury at the end of 18 hours of cold storage, lungs were flushed with 1 ml of normal saline, and perfusates assayed for lactate dehydrogenase (Biovision, Milpitas, CA) and HMGB1 (LifeSpan Biosciences, Inc., Seattle, WA) levels via ELISA, according to the manufacturers' recommendation.
| Lung function
Dual-chamber whole-body plethysmography was performed as de- 
| Histology
Lungs were inflated en-bloc with 10% buffered formaldehyde at either 6 hours or 5 days post-LTx and subsequently paraffin processed, sectioned and stained. Injury was graded in pre-and posttransplant ischemia reperfusion lungs as previously described. [34] [35] [36] For rejection studies, sections were scored by a lung pathologist (MG) blinded to the experimental conditions using standard criteria (International Society for Heart and Lung Transplantation [ISHLT] A Grade). BD Pharmingen) using ImmPress visualization (Vector Laboratories, Burlingame, CA) as previously described. 10 All staining was evaluated in a blinded fashion (CA and MG). Controls consisted of isotype controls and omission of primary antibodies. Table S1 .
| Quantitative RT-PCR
| Bronchoalveolar Lavage (BAL)
Left lung BAL was performed at 6 hours posttransplantation by instilling 3-0.5mL aliquots of ice cold PBS with intermittent aspiration.
Fluid was centrifuged, supernatant collected, and ELISA analysis for of albumin (Genway Biotech, San Diego, CA) and HMGB1 performed per manufacturer instructions.
| Statistics
GraphPad Prism version 7.0 for Mac OS X (GraphPad, San Diego, 
| RE SULTS
| BD induces donor lung injury
In keeping with previous studies, 3 hours of donor maintenance post-BD induction led to significant donor lung injury. 34 BD donor lungs demonstrated increased pathologic injury scores based on histologic analysis when compared to sham and LD lungs ( Figure 1A -B).
Brain death injury was associated with a significant increase in infiltration of both neutrophils and macrophages in BD lungs compared to LD lungs, as determined by quantification of immunohistochemistry staining ( Figure 1C ). 
| Histological changes and inflammatory markers associated with BD induction were not exacerbated during the cold storage period
In vivo LTx studies were carried out as depicted in Figure Figure 4D ). Lungs exposed to 18 hours of CS were insignificantly different from their corresponding pre-CS groups. Similar to pathologic injury scoring of these lungs, C3aRA treatment of BD lungs had no effect on inflammatory cytokine expression.
| C3aRA abrogates early post-LTx ischemiareperfusion injury and inflammation associated with donor BD
Given the susceptibility and sensitivity of lungs to injury, as well as the In terms of complement activation, we showed that BD exacerbates C3d deposition when compared to LD, and that C3aRA treatment has no impact on C3d deposition, with an expression pattern and intensity not dissimilar to the BD group ( Figure 6B ). While C3aRA Figure 6D ). This pattern was also found for TGF-β expression.
| Donor brain death significantly exacerbates lung allograft rejection
To assess the impact of BD in LTx on acute rejection (AR) and determine the therapeutic potential of BD lung targeted C3aRA in a clinically relevant setting, we performed allograft transplants. The allograft pairing utilized in these studies generates robust grade 3-4 AR at 7 days post-LTx, 42 and therefore here given that we hypothesize BD will exacerbate AR, we harvested allografts at 5 days post-LTx. To confirm allograft functionality, we performed serial Human and animal studies, mainly in heart and kidney transplantation, have demonstrated a multitude of injurious processes and pathways activated by BD. 34, 39, 43 However, despite these studies, the BD model has largely been underutilized in LTx studies. Studies in rodents confirm our findings that BD induces the development of a proinflammatory state 44 that has the potential to adversely affect posttransplant outcomes. As a result, the mechanisms that contribute to donor organ injury, how these pretransplant injuries modulate posttransplant outcomes, and more importantly how these insults can be combated have been underinvestigated.
| D ISCUSS I ON
In our lung BD studies, we corroborated previous findings that BD is associated with a time dependent increase in pulmonary inflammation, particularly neutrophilia, and endothelial activation. 34 Studies have shown that BD induces complement activation in donor hearts and kidneys, increases systemic complement activity, and exacerbates posttransplant IRI and rejection. 4, 10, 15 In contrast, we did not detect any differences in C3d or complement gene expression between LD and BD donor lungs, albeit our analysis was at an earlier time point. However, in accordance with previous heart and kidney transplant studies, we did demonstrate a significant increase in C3d at physiological temperatures, fluid environment, and aeration, and is an approach that has been explored with success by others. [54] [55] [56] To remain consistent with the relevant clinical scenario, we in- We and others have previously demonstrated a similar phenomenon in heart and kidney transplant models, where systemic or graft targeted C-Inh improved BD organ graft survival. 10, 17 The use of C3aRA, as opposed to broad spectrum C3 inhibitors used by others, enables C3 opsonic functions to remain intact, and accordingly we show no significant difference in C3d deposition between BD and BD C3aRA groups. Further, our previous studies have shown and C3a share the alternative receptor RAGE (receptor for advanced glycation end-products), which has been implicated in a number of disease processes including TBI-associated inflammation and pulmonary dysfunction, with effects on post-LTx outcomes.
39, 57
Somewhat surprisingly, we could not demonstrate any difference to early extubation in a significantly higher proportion of LTx patients in a small randomized control trial. 22 Whether this led to any longterm benefits has yet to be reported, but taken together, these clinical and experimental data lend support for a rationale to utilize C-Inh as a means to ameliorate IRI-and BD-induced IRI. The inclusion of nebulized complement therapeutics as part of the lung donor management protocol, or within ex vivo lung perfusion, may well enable the utilization of marginal donor lungs by mitigating the more severe IRI associated with the use of these extended criteria donors.
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